Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Fluvastatin inhibits hepatitis C replication in humans.

Bader T, Fazili J, Madhoun M, Aston C, Hughes D, Rizvi S, Seres K, Hasan M.

Am J Gastroenterol. 2008 Jun;103(6):1383-9. doi: 10.1111/j.1572-0241.2008.01876.x. Epub 2008 Apr 14.

PMID:
18410471
2.

Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin.

Nahmias Y, Goldwasser J, Casali M, van Poll D, Wakita T, Chung RT, Yarmush ML.

Hepatology. 2008 May;47(5):1437-45. doi: 10.1002/hep.22197.

3.

Predictors of response of US veterans to treatment for the hepatitis C virus.

Backus LI, Boothroyd DB, Phillips BR, Mole LA.

Hepatology. 2007 Jul;46(1):37-47.

PMID:
17567830
4.

Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial.

O'Leary JG, Chan JL, McMahon CM, Chung RT.

Hepatology. 2007 Apr;45(4):895-8.

PMID:
17393518
5.

Statins and HCV: a complex issue.

Lonardo A, Loria P, Bertolotti M, Carulli N.

Hepatology. 2007 Jan;45(1):257. No abstract available.

PMID:
17187410
6.

Hepatitis C virus entry: molecular biology and clinical implications.

Barth H, Liang TJ, Baumert TF.

Hepatology. 2006 Sep;44(3):527-35. Review.

PMID:
16941688
7.

Different anti-HCV profiles of statins and their potential for combination therapy with interferon.

Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N.

Hepatology. 2006 Jul;44(1):117-25.

PMID:
16799963
8.

Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients.

Nielsen SU, Bassendine MF, Burt AD, Martin C, Pumeechockchai W, Toms GL.

J Virol. 2006 Mar;80(5):2418-28.

9.
10.

Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids.

Kapadia SB, Chisari FV.

Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2561-6. Epub 2005 Feb 7.

11.

Elevated prevalence of hepatitis C infection in users of United States veterans medical centers.

Dominitz JA, Boyko EJ, Koepsell TD, Heagerty PJ, Maynard C, Sporleder JL, Stenhouse A, Kling MA, Hrushesky W, Zeilman C, Sontag S, Shah N, Ona F, Anand B, Subik M, Imperiale TF, Nakhle S, Ho SB, Bini EJ, Lockhart B, Ahmad J, Sasaki A, van der Linden B, Toro D, Martinez-Souss J, Huilgol V, Eisen S, Young KA.

Hepatology. 2005 Jan;41(1):88-96.

PMID:
15619249
12.

Hepatitis C tested prevalence and comorbidities among veterans in the US Northwest.

Sloan KL, Straits-Tröster KA, Dominitz JA, Kivlahan DR.

J Clin Gastroenterol. 2004 Mar;38(3):279-84.

PMID:
15128077
13.

Future trends in managing hepatitis C.

McHutchison JG, Dev AT.

Gastroenterol Clin North Am. 2004 Mar;33(1 Suppl):S51-61.

PMID:
15081103
14.

Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation.

Ye J, Wang C, Sumpter R Jr, Brown MS, Goldstein JL, Gale M Jr.

Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15865-70. Epub 2003 Dec 10.

15.

Topology of the membrane-associated hepatitis C virus protein NS4B.

Lundin M, Monné M, Widell A, Von Heijne G, Persson MA.

J Virol. 2003 May;77(9):5428-38.

16.

Current therapy for hepatitis C: pegylated interferon and ribavirin.

McHutchison JG, Fried MW.

Clin Liver Dis. 2003 Feb;7(1):149-61. Review.

PMID:
12691464
17.

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J.

N Engl J Med. 2002 Sep 26;347(13):975-82.

18.

Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex.

Egger D, Wölk B, Gosert R, Bianchi L, Blum HE, Moradpour D, Bienz K.

J Virol. 2002 Jun;76(12):5974-84.

19.

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK.

Lancet. 2001 Sep 22;358(9286):958-65.

PMID:
11583749
20.

Clinically relevant differences between the statins: implications for therapeutic selection.

Chong PH, Seeger JD, Franklin C.

Am J Med. 2001 Oct 1;111(5):390-400. Review.

PMID:
11583643

Supplemental Content

Support Center